The future of women’s health therapeutics is here.
Celmatix Therapeutics is pioneering a new category: ovarian health
We coined this term in 2020 to emphasize the key functions of the ovary beyond reproduction.
The ovary is in the center of a complex endocrine signaling network. When it does not function properly, women experience serious health problems.
Despite often debilitating symptoms, such conditions are still being treated with hormonal interventions introduced more than 50 years ago.
1 in 3 women
have conditions such as endometriosis, premature menopause, and polycystic ovary syndrome (PCOS), which are rooted in ovarian dysfunction. These conditions are debilitating and cause significant comorbidities.
Poor ovarian health leads to:
Heart disease
Stroke
Bone density loss
Neurocognitive decline
Autoimmune disorders
Diabetes
Obesity
We believe that female biology is unique, and that women deserve therapeutics made specifically for them so they can live longer, healthier lives.
Immune Function • Glucose Metabolism • Bone Health • Mental Health • Sleep • Pregnancy • Sexual function
Ovarian Health Impacts:
Celmatix was awarded $3.5 million in non-dilutive capital by ARPA-H to advance our AMH receptor agonist program.
The Advanced Research Program Agency for Health is a new organization tasked by the U.S. government to advance medical breakthroughs at “warp speed.”
Celmatix is the only company to be awarded a SPARK contract in the Ovarian Health category.
This competitive award allows our ovarian aging program to advance rapidly, with the U.S. government as our strategic partner from discovery through regulatory clearance and reimbursement.
Women are living longer, but they are not always thriving.
While the ovary is a crucial regulator of a woman’s health and longevity, it is the only organ that ceases to function decades ahead of our lifespan.
Modern women need all their organs, including their ovaries, to function better throughout their lifespans.
Celmatix is creating the transformative women’s health drugs of the future.
About us
Our approach centers new biology and novel approaches to solve long standing problems.
Based in New York City and Cambridge, MA, we are a preclinical-stage biotech focused on groundbreaking therapies for women’s health. With our growing pipeline of innovative drug programs including an AMHR2 agonist program focused on ovarian aging, an oral FSH receptor agonist for infertility, and an immunotherapy for endometriosis, Celmatix Therapeutics is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health, ushering in a new era in the field.
A New Era in Women’s Therapeutics
Our decade-long multi-omic research related to ovarian biology gave us unique insights into the key molecules and pathways underlying ovarian function. These insights, in turn, have resulted in these retained and partnered drug programs, which are already expanding the MOA landscape in women’s health beyond the HPA axis.
Modern women need real treatments for conditions that uniquely impact them, like Polycystic Ovary Syndrome (PCOS) and endometriosis.
Our pipeline
Celmatix Therapeutics is paving the way forward.
The proof is in our pipeline.
Despite the urgent unmet need in women’s health, few therapies exist to treat the high prevalence of women’s health conditions.
Modern women outlive the function of their ovaries by decades–sometimes half a century–and as a result experience menopause. The physiological disruptions from menopause are the greatest accelerants of unhealthy aging for modern women.
Our groundbreaking drug pipeline is the future of women’s health.
4
Drug programs
2
Modalities
3
Lead indications
